Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03125577
Other study ID # GIMI-IRB-17005
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 15, 2017
Est. completion date December 2021

Study information

Verified date September 2019
Source Shenzhen Geno-Immune Medical Institute
Contact Lung-Ji Chang, PhD
Phone +86-0755 8672-5195
Email c@szgimi.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.


Description:

Background:

T cells modified with lentiviral chimeric antigen receptor (CAR) gene have been studied in different clinical settings. Recent successes suggest that increased costimulatory signaling in the CAR design is critical for long term efficacy. Several clinical reports indicate that many patients still relapse and developed CD19-negative cancer cells after CD19 targeted therapy. Thus, to prevent the target escapes and improve the therapeutic effects, CAR gene-modified T cells targeting CD20, CD22, CD30, CD38, CD70 or CD123 are considered to apply together with CD19 CAR-T cells.

Activation of T cell response to high tumor burden may induce a severe response. To increase safety, a novel design using an inducible caspase 9 fusion gene has been incorporated in the CAR gene. A 4th generation CAR lentiviral vector (4SCAR) carrying multiple costimulatory signals for CD28/CD137/CD27 plus an inducible apoptotic caspase 9 gene has been established. This study aims to evaluate the activities of a combination of CAR gene-modified T cells to target cancer cells based on specific CD19/CD20/CD22/CD30/CD38/CD70/CD123 single chain antibody gene designs (4SCAR19/20/22/30/38/70/123).

Objective:

To evaluate safety and efficacy of administrating 4SCAR19, 4SCAR20, 4SCAR22, 4SCAR30, 4SCAR38, 4SCAR70 and 4SCAR123 T cells to patients with mixed CD19 positive and negative B cell malignancies following a cyclophosphamide/fludarabine based conditioning regimen.

Eligibility:

Patients older than 6-month-old with CD19 positive or negative B cell malignancies that have recurred after or refractory to standard therapy and is deemed incurable using standard treatment.

Design:

Participants will be screened based on cancer cell phenotype analyzed using flow cytometry or immunohistochemical staining methods. Peripheral blood mononuclear cells (PBMC) will be obtained through apheresis. On Day -5 to -7, T cells from PBMC will be activated and enriched, which will be followed by 4SCAR19, 4SCAR20, 4SCAR22, 4SCAR30, 4SCAR38, 4SCAR70 and 4SCAR123 lentiviral transduction. The total cell preparation time is approximately 5-7 days. Participants will receive a preparative conditioning regimen comprising cyclophosphamide/fludarabine to prepare their immune system to accommodate the modified CAR T cells. The preparative regimen will depend on the immune condition of patients, which is consistent with standard chemotherapy conditioning regimen. Participants will receive an infusion of the modified 4SCAR19 and 4SCAR20/22/30/38/70/123 T cells and closely followed up for treatment-related responses. Participants will be continuously monitored for CAR T cells and clinical responses in a preset timeline.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2021
Est. primary completion date July 31, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Months to 75 Years
Eligibility Inclusion Criteria:

1. age older than 6 months.

2. malignant B cell surface expression of CD19/CD20/CD22/CD30/CD38/CD70/CD123 molecules.

3. the KPS score over 80 points, and survival time is more than 1 month.

4. greater than Hgb 80 g/L.

5. no contraindications to blood cell collection.

Exclusion Criteria:

1. accompanied with other active diseases, the treatment is difficult to assess patient response.

2. bacteria, fungus, or virus infection, unable to control.

3. living with HIV.

4. active HBV and HCV infection.

5. pregnant and nursing mothers.

6. under systemic steroid treatment within a week of the treatment.

7. prior failed CAR-T treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
4SCAR19 and 4SCAR22
4SCAR19 and 4SCAR22
4SCAR19 and 4SCAR38
4SCAR19 and 4SCAR38
4SCAR19 and 4SCAR20
4SCAR19 and 4SCAR20
4SCAR19 and 4SCAR123
4SCAR19 and 4SCAR123
4SCAR19 and 4SCAR70
4SCAR19 and 4SCAR70
4SCAR19 and 4SCAR30
4SCAR19 and 4SCAR30

Locations

Country Name City State
China Zhujiang Hospital of Southern Medical University Guangzhou Guangdong
China Zhujiang Hospital of Southern Medical University Guangzhou Guangdong
China Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center Kunming Yunnan
China Shenzhen Geno-immune Medical Institute Shenzhen Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen Geno-Immune Medical Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of fourth generation anti CD19 and CD20/CD22/CD30/CD38/CD70/CD123 CAR-T cells in patients with relapsed B cell malignancies using CTCAE 4 standard to evaluate the level of adverse events standard to evaluate the level of adverse events physiological parameter (for safety, measuring cytokine response, fever, symptoms) 24 weeks
Secondary Anti tumor activity of fourth generation anti CD19 and CD20/CD22/CD30/CD38/CD70/CD123 CAR-T cells in patients with relapsed or refractory B cell malignancies scale of CAR copies and leukemic cell burden (for efficacy) 1 year
See also
  Status Clinical Trial Phase
Completed NCT02343120 - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Phase 1/Phase 2
Completed NCT02018861 - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Phase 1/Phase 2
Terminated NCT03701438 - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT04551963 - Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Phase 1
Recruiting NCT05683717 - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Completed NCT01775631 - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Phase 1
Active, not recruiting NCT01905813 - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Phase 1
Recruiting NCT05275504 - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Active, not recruiting NCT02457598 - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Phase 1
Recruiting NCT03050190 - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT04170283 - Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies Phase 3
Recruiting NCT04509700 - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Phase 2
Not yet recruiting NCT03642496 - Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies Early Phase 1
Completed NCT00983619 - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies Phase 1/Phase 2